Menu
Search
|

Menu

Close
X

Atossa Genetics Inc ATOS.OQ (NASDAQ Stock Exchange Capital Market)

3.68 USD
-0.05 (-1.34%)
As of Mar 22
chart
Previous Close 3.73
Open 3.66
Volume 150,921
3m Avg Volume 502,142
Today’s High 3.91
Today’s Low 3.58
52 Week High 7.55
52 Week Low 0.81
Shares Outstanding (mil) 11.70
Market Capitalization (mil) 6.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-6.428
FY17
-22.398
FY16
-26.885
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
--
8.39
Price to Book (MRQ)
vs sector
1.90
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.02
LT Debt to Equity (MRQ)
vs sector
0.00
11.35
Return on Investment (TTM)
vs sector
-240.28
13.82
Return on Equity (TTM)
vs sector
-338.79
15.24

EXECUTIVE LEADERSHIP

Kyle Guse
Chief Financial Officer, General Counsel, Secretary, Since 2013
Salary: $364,000.00
Bonus: --
Shu-Chih Chen
Director, Since 2014
Salary: $224,268.00
Bonus: --
Stephen Galli
Independent Director, Since 2011
Salary: --
Bonus: --
H. Lawrence Remmel
Independent Director, Since 2012
Salary: --
Bonus: --
Richard Steinhart
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

107 Spring St
SEATTLE   WA   98104-1005

Phone: +1206.5880256

Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

SPONSORED STORIES